Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
出版年份 2020 全文链接
标题
Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
作者
关键词
-
出版物
Cancers
Volume 12, Issue 12, Pages 3731
出版商
MDPI AG
发表日期
2020-12-14
DOI
10.3390/cancers12123731
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Overview of AKR1C3: Inhibitor Achievements and Disease Insights
- (2020) Yang Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?
- (2020) Eva Novotná et al. ARCHIVES OF TOXICOLOGY
- Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism
- (2020) Anselm Morell et al. ARCHIVES OF TOXICOLOGY
- Potent and Highly Selective Aldo–Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
- (2019) Kshitij Verma et al. JOURNAL OF MEDICINAL CHEMISTRY
- The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents
- (2019) Sung-Han Hsiao et al. CANCER LETTERS
- Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3
- (2019) Neslihan Bukum et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
- (2019) Ning Ji et al. Frontiers in Oncology
- Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile
- (2018) Eva Novotná et al. ARCHIVES OF TOXICOLOGY
- Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment
- (2018) Eva Novotná et al. BIOCHEMICAL PHARMACOLOGY
- Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy
- (2017) V K Patel et al. LEUKEMIA
- Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10
- (2017) Zhen Zhou et al. Molecular Medicine Reports
- Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells
- (2016) Lianne E. Rotin et al. LEUKEMIA & LYMPHOMA
- Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines
- (2016) Kshitij Verma et al. ACS Medicinal Chemistry Letters
- Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro
- (2015) Daniela Cihalova et al. BIOCHEMICAL PHARMACOLOGY
- FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation
- (2015) T. Oellerich et al. BLOOD
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targets for Ibrutinib Beyond B Cell Malignancies
- (2015) A. Berglöf et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Calculating an optimal box size for ligand docking and virtual screening against experimental and predicted binding pockets
- (2015) Wei P. Feinstein et al. Journal of Cheminformatics
- Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells
- (2014) Toshiyuki Matsunaga et al. ANTI-CANCER DRUGS
- In vitro,in vivoandex vivocharacterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1
- (2014) Hui Zhang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells
- (2014) Lesley A. Mathews Griner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3
- (2014) Jakub Hofman et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia
- (2013) S. A. Rushworth et al. BLOOD
- Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
- (2013) Ramya Vadlapatla et al. CURRENT PHARMACEUTICAL DESIGN
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- ZINC: A Free Tool to Discover Chemistry for Biology
- (2012) John J. Irwin et al. Journal of Chemical Information and Modeling
- Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetonein vitro
- (2012) Lucie Skarydova et al. XENOBIOTICA
- Aldo–Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers
- (2012) Toshiyuki Matsunaga et al. Frontiers in Pharmacology
- Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers
- (2012) Brian Laffin et al. Frontiers in Pharmacology
- The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy
- (2011) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group
- (2011) Linlin Zhong et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progressioan
- (2010) Mikhail G Dozmorov et al. BMC CANCER
- Naturally Occurring Variants of Human Aldo-Keto Reductases with Reduced In Vitro Metabolism of Daunorubicin and Doxorubicin
- (2010) O. S. Bains et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis
- (2010) Julie A Di Paolo et al. Nature Chemical Biology
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading
- (2009) Oleg Trott et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
- (2009) Garrett M. Morris et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer
- (2009) Michael C. Byrns et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis
- (2009) Jane Birtwistle et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids
- (2008) Lucie Škarydová et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired
- (2008) A. Jo Chien et al. SEMINARS IN ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More